[肝细胞癌早期诊治技术的研究进展及临床应用]。

Q3 Medicine
Y M Nan, S X Zhao, L D Liu
{"title":"[肝细胞癌早期诊治技术的研究进展及临床应用]。","authors":"Y M Nan, S X Zhao, L D Liu","doi":"10.3760/cma.j.cn501113-20250314-00093","DOIUrl":null,"url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is a malignant tumor that endangers human health globally. Diagnosis and treatment at an early stage are the keys to receiving radical treatment and improving survival rates. A clinical solution for HCC diagnosis at an early stage is the combination of serum markers and imaging technology. A basic strategy for screening and diagnosis at an early stage with a favorable cost-effectiveness ratio is the alpha-fetoprotein combined with abdominal ultrasound. The HCC diagnostic rate at an early stage can be improved with AFP combined with des-gamma carboxy prothrombin, aldehyde-keto reductase 1B10, liquid biopsy, and imaging tests. The radical treatment for early-stage HCC has entered a new era of diversification. The effectiveness of radical treatment can assist in improving the combined use of small molecule targeted medications and immune checkpoint inhibitors. The prevention and control of liver cancer will move toward a new stage of greater precision and efficiency with the advancement of biotechnology and policy promotion.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 4","pages":"307-309"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Research progress and clinical application in the early diagnosis and treatment technology of hepatocellular carcinoma].\",\"authors\":\"Y M Nan, S X Zhao, L D Liu\",\"doi\":\"10.3760/cma.j.cn501113-20250314-00093\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Hepatocellular carcinoma (HCC) is a malignant tumor that endangers human health globally. Diagnosis and treatment at an early stage are the keys to receiving radical treatment and improving survival rates. A clinical solution for HCC diagnosis at an early stage is the combination of serum markers and imaging technology. A basic strategy for screening and diagnosis at an early stage with a favorable cost-effectiveness ratio is the alpha-fetoprotein combined with abdominal ultrasound. The HCC diagnostic rate at an early stage can be improved with AFP combined with des-gamma carboxy prothrombin, aldehyde-keto reductase 1B10, liquid biopsy, and imaging tests. The radical treatment for early-stage HCC has entered a new era of diversification. The effectiveness of radical treatment can assist in improving the combined use of small molecule targeted medications and immune checkpoint inhibitors. The prevention and control of liver cancer will move toward a new stage of greater precision and efficiency with the advancement of biotechnology and policy promotion.</p>\",\"PeriodicalId\":24006,\"journal\":{\"name\":\"中华肝脏病杂志\",\"volume\":\"33 4\",\"pages\":\"307-309\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-04-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中华肝脏病杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/cma.j.cn501113-20250314-00093\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华肝脏病杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.cn501113-20250314-00093","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

肝细胞癌(HCC)是危害人类健康的全球性恶性肿瘤。早期诊断和治疗是接受根治性治疗和提高生存率的关键。早期诊断HCC的临床解决方案是结合血清标志物和影像学技术。早期筛查和诊断的基本策略是甲胎蛋白结合腹部超声,具有良好的成本-效果比。AFP联合去γ羧基凝血酶原、醛酮还原酶1B10、液体活检和影像学检查可提高早期HCC的诊断率。早期HCC的根治性治疗进入了多元化的新时代。根治性治疗的有效性可以帮助改善小分子靶向药物和免疫检查点抑制剂的联合使用。随着生物技术的进步和政策的推动,肝癌的防治将迈向更加精准和高效的新阶段。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[Research progress and clinical application in the early diagnosis and treatment technology of hepatocellular carcinoma].

Hepatocellular carcinoma (HCC) is a malignant tumor that endangers human health globally. Diagnosis and treatment at an early stage are the keys to receiving radical treatment and improving survival rates. A clinical solution for HCC diagnosis at an early stage is the combination of serum markers and imaging technology. A basic strategy for screening and diagnosis at an early stage with a favorable cost-effectiveness ratio is the alpha-fetoprotein combined with abdominal ultrasound. The HCC diagnostic rate at an early stage can be improved with AFP combined with des-gamma carboxy prothrombin, aldehyde-keto reductase 1B10, liquid biopsy, and imaging tests. The radical treatment for early-stage HCC has entered a new era of diversification. The effectiveness of radical treatment can assist in improving the combined use of small molecule targeted medications and immune checkpoint inhibitors. The prevention and control of liver cancer will move toward a new stage of greater precision and efficiency with the advancement of biotechnology and policy promotion.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
中华肝脏病杂志
中华肝脏病杂志 Medicine-Medicine (all)
CiteScore
1.20
自引率
0.00%
发文量
7574
期刊介绍:
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信